90 results about "Epidermal Dendritic Cells" patented technology

The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.

α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.

Provided is a novel method capable of manufacturing an artificial skin model including dendritic cells. A method for manufacturing an artificial skin model includes the following: forming a dermal tissue layer by culturing coated cells in which a cell surface is coated with a coating film containing an extracellular matrix component, so that the coated cells are layered; forming a basal layer including type IV collagen on the dermal tissue layer by bringing type IV collagen into contact with the dermal tissue layer; and forming an epidermal layer by arranging epidermal cells on the basal layer. At least one of the dermal tissue layer and the epidermal layer includes dendritic cells.

An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X₁=a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X₂=a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

The invention discloses organic rice flour capable of enhancing immunity of infants. A formula comprises organic rice, glucose, hawthorn, salt-processed fructus alpiniae oxyphyllae, medlar, pine nut, composite vitamins and composite minerals. The organic rice flour disclosed by the invention has the advantages that a biological enzymolysis technology is utilized for improving the degree of gelatinization of rice starch, the problems of shortage of enteral amylase of the infants and indigestion caused by intake of non-gelatinized starch can be effectively solved, and the digestive absorption index can be obviously improved in comparison with a traditional rice flour processing technology. An extract of the medlar contains lycium barbarum polysaccharides, has the effect of promoting humoral immunity, cellular immunity and erythrocyte immunity, and can promote the function exertion of mononuclear macrophages, NK (natural killer) cells, plaque forming cells, dendritic cells and cell factors and play a positive role in receptor expression, signal conduction and a nerve-endocrine-immune network.

Disclosed are a novel seven-pass transmembrane receptor protein found in immature dendritic cells and a DNA encoding the same. Further, disclosed are a replicable recombinant DNA which comprises a replicable expression vector and, operably inserted therein, the above-mentioned DNA; a cell of a microorganism or cell culture (transformant), which is transformed with the above-mentioned replicable recombinant DNA; a seven-pass transmembrane receptor protein which is produced on the cell surface of the above-mentioned transformant; a method for screening a ligand which binds to the above-mentioned seven-pass transmembrane receptor protein, and a method for screening a substance which inhibits the ligand from binding to the seven-pass transmembrane receptor protein; and an antibody which binds to the above-mentioned seven-pass transmembrane receptor protein. The present invention also discloses a method for the diagnosis of an inflammatory disease, such as rheumatism, which comprises determining the amount of the seven-pass transmembrane receptor protein expressed in human leukocytes.

The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.

The invention provides a preparation method of rapamycin nano-micelle eye drops. The preparation method comprises the following steps: mixing a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol grafting polymer, rapamycin, absolute ethyl alcohol and glucose to obtain a mixed solution containing the rapamycin; carrying out evaporation and hydration steps on the mixed solution containing the rapamycin and putting the mixed solution on ice; treating in an ice bath until the mixed solution is transparent, so as to obtain the rapamycin nano-micelle eye drops. A result of the embodiment of the invention shows that after the rapamycin nano-micelle eye drops are used for treating, corneal grafts of mice and rabbits continuously keep transparent; the rapamycin nano-micelle eye drops can be used for effectively prolonging the survival time of the corneal grafts; the rapamycin nano-micelle eye drops can be used for effectively reducing inflammatory cell infiltration, inhibiting corneal edema and maintaining normal structures of the corneal grafts; CD11b+macrophage, Ly6G+neutrophil, CD11c+dendritic cells and CD4+T cells, which are infiltrated in the corneal grafts, are remarkably reduced.

The invention relates to dendritic cells produced from human induced pluripotent stems cells (iPSC). The invention also relates to methods for making and methods of using the dendritic cells of the invention.

The invention discloses an in vitro culture method for promoting maturation of dendritic cells and special culture medium for the method. The invention provides a maturation promoting culture medium prepared from in vitro immature dendritic cells. The method includes mixing R848 and PGE2 with serum-free AIM-V culture medium to obtain a culture medium, the concentration of R848 in the maturation promoting culture medium being (1-10) mu g/mL, the concentration of PGE2 in the maturation promoting culture medium being 1 mu g/mL. The inventive experiment shows that the inventive maturation promoting culture medium is superior to the control standard culture medium. The inventive maturation promoting culture medium has few stimulating factors, strong DC maturation promoting capacity, and high survival rate of DC after maturation promotion.

The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, and (d) a cell toxin.